Feature
Article
Pharmaceutical Commerce Presents The Most Favored Nation Mandate
Author(s):
Key Takeaways
- The executive order requires US drug prices to match the lowest international prices, treating the US as a most-favored-nation.
- Letters were sent to 17 major pharmaceutical companies, urging compliance with the order by fall.
Join us for this premium webinar on September 10!
Earlier this year, Donald Trump issued an executive order stating that pharma companies must treat the United States as a most-favored-nation (MFN). Essentially, the order states that drug prices in the US should at least match the lowest price across the international markets. This summer, the President doubled down on the order when he published letters to 17 major pharmaceutical companies saying that they had not fulfilled the requirements of the order and that they had until the fall to work with the White House on bringing drug prices down.
Join Pharmaceutical Executive on Wednesday, September 10, as it sits down with industry experts and insiders for a premium webinar discussing the key questions surrounding the MFN order. Who will benefit? Who stands to lose? What are the patient access implications? Should the industry expect market and payer disruptions?
Click here to sign up!
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
